[
  {
    "ts": null,
    "headline": "BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?",
    "summary": "BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.",
    "url": "https://finnhub.io/api/news?id=d5a61384b04614f81fd439ef3c9e9f187c46cc0736fb314dddc99557548bae90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770650940,
      "headline": "BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?",
      "id": 138609129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.",
      "url": "https://finnhub.io/api/news?id=d5a61384b04614f81fd439ef3c9e9f187c46cc0736fb314dddc99557548bae90"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Most Profitable Undervalued Stocks to Buy On February 6, 2026, Guggenheim raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) to $72 from $62 and reiterated a Buy rating. The firm significantly increased its estimated probability of success for iber/mezi to 90% from 33% and lifted its […]",
    "url": "https://finnhub.io/api/news?id=3baa468eac889880784224c35188de479ca861397b9a9fe08bacddb7ce6331ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770644037,
      "headline": "Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating",
      "id": 138415894,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Most Profitable Undervalued Stocks to Buy On February 6, 2026, Guggenheim raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) to $72 from $62 and reiterated a Buy rating. The firm significantly increased its estimated probability of success for iber/mezi to 90% from 33% and lifted its […]",
      "url": "https://finnhub.io/api/news?id=3baa468eac889880784224c35188de479ca861397b9a9fe08bacddb7ce6331ba"
    }
  },
  {
    "ts": null,
    "headline": "Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence",
    "summary": "BAAR, Switzerland, February 09, 2026--Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence",
    "url": "https://finnhub.io/api/news?id=7617dd93760f4fe0f71ca9a8f8dd430bf211ded41b91112e25753621a7e006cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770616800,
      "headline": "Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence",
      "id": 138400016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BAAR, Switzerland, February 09, 2026--Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence",
      "url": "https://finnhub.io/api/news?id=7617dd93760f4fe0f71ca9a8f8dd430bf211ded41b91112e25753621a7e006cb"
    }
  }
]